logo
CanyamAI summaries for academic research
language
MobileMobile
  • Phone FeatureWeChat Mini Program
EnglishEnglish
noticeNotice
BlogBlog
delete
arrow
Return

Ultra-hypofractionated stereotactic ablative body radiotherapy for primary renal cell carcinoma: 5-year outcomes from a pooled analysis of the FASTRACK trials

delete2026-05-17
delete0
PRE
AI
S
Shankar Siva *
M
Muhammad Ali
N
Nicholas Hardcastle
T
Tomas Kron
B
Braden Higgs
F
Farshad Foroudi
J
Jeremy Ruben
S
Sree Appu
J
Jarad Martin
S
Swetha Sridharan
R
Rebecca Montgomery
R
Ryan Davey
C
Charles Lin
M
Mark Shaw
S
Sarat Chander
M
Mark Sidhom
B
Ben G L Vanneste
D
Declan G Murphy
N
Nathan Lawrentschuk
D
David Pryor
DOI：10.1016/S1470-2045(26)00170-1delete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
Stereotactic ablative body radiotherapy (SABR) is a non-invasive therapy for inoperable primary renal cell carcinoma. However, long-term prospective clinical trial data are scarce. We aimed to use pooled data from two clinical trials (FASTRACK and FASTRACK II) to evaluate activity and safety of SABR in the long term.
Keywords:
Stereotactic ablative body radiotherapy
Renal cell carcinoma
Hypofractionated radiotherapy
Long-term outcomes
Pooled analysis

Journal

T
The Lancet Oncology
IF:
0
Papers:
348
Citations:
1

Organization

No organization information available